EP1385983A4 - IN VIVO METHODS FOR DETERMINING THE ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS - Google Patents

IN VIVO METHODS FOR DETERMINING THE ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS

Info

Publication number
EP1385983A4
EP1385983A4 EP02719386A EP02719386A EP1385983A4 EP 1385983 A4 EP1385983 A4 EP 1385983A4 EP 02719386 A EP02719386 A EP 02719386A EP 02719386 A EP02719386 A EP 02719386A EP 1385983 A4 EP1385983 A4 EP 1385983A4
Authority
EP
European Patent Office
Prior art keywords
receptor
kinase inhibitors
vivo methods
determining activity
type kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02719386A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1385983A1 (en
Inventor
Kenneth A Thomas Jr
Xianzhi Mao
Richard L Kendall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP1385983A1 publication Critical patent/EP1385983A1/en
Publication of EP1385983A4 publication Critical patent/EP1385983A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP02719386A 2001-04-02 2002-03-29 IN VIVO METHODS FOR DETERMINING THE ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS Withdrawn EP1385983A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28077101P 2001-04-02 2001-04-02
US280771P 2001-04-02
PCT/US2002/009758 WO2002079498A1 (en) 2001-04-02 2002-03-29 In vivo methods of determining activity of receptor-type kinase inhibitors

Publications (2)

Publication Number Publication Date
EP1385983A1 EP1385983A1 (en) 2004-02-04
EP1385983A4 true EP1385983A4 (en) 2005-11-16

Family

ID=23074563

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02719386A Withdrawn EP1385983A4 (en) 2001-04-02 2002-03-29 IN VIVO METHODS FOR DETERMINING THE ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS

Country Status (4)

Country Link
EP (1) EP1385983A4 (cg-RX-API-DMAC10.html)
JP (1) JP2004527244A (cg-RX-API-DMAC10.html)
CA (1) CA2443144A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002079498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
EA017648B1 (ru) 2007-09-14 2013-02-28 Орто-Макнейл-Янссен Фармасьютикалз, Инк. 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
JP5690277B2 (ja) 2008-11-28 2015-03-25 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102439015B (zh) 2009-05-12 2015-05-13 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0566226A1 (en) * 1992-01-20 1993-10-20 Zeneca Limited Quinazoline derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0566226A1 (en) * 1992-01-20 1993-10-20 Zeneca Limited Quinazoline derivatives

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHRISTENSEN J G ET AL: "High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. DEC 2001, vol. 7, no. 12, December 2001 (2001-12-01), pages 4230 - 4238, XP009044605, ISSN: 1078-0432 *
MCLAY I M ET AL: "The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 9, 2001, pages 537 - 554, XP002248371, ISSN: 0968-0896 *
MENDEL D B ET AL: "The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. DEC 2000, vol. 6, no. 12, December 2000 (2000-12-01), pages 4848 - 4858, XP002319665, ISSN: 1078-0432 *
POLLACK V A ET AL: "INHIBITION OF EPIDERMAL GROWTH FACTOR RECEPTOR-ASSOCIATED TYROSINE PHOSPHORYLATION IN HUMAN CARCINOMAS WITH CP-358,774: DYNAMICS OF RECEPTOR INHIBITION IN SITU AND ANTITUMOR EFFECTS IN ATHYMIC MICE", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 291, no. 2, 1999, pages 739 - 748, XP001014737, ISSN: 0022-3565 *
See also references of WO02079498A1 *
SEPP-LORENZINO L ET AL: "A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo", CANCER RESEARCH 15 JAN 2004 UNITED STATES, vol. 64, no. 2, 15 January 2004 (2004-01-15), pages 751 - 756, XP001205456, ISSN: 0008-5472 *
VINCENT P W ET AL: "Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts.", CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2000, vol. 45, no. 3, 2000, pages 231 - 238, XP002319666, ISSN: 0344-5704 *
WEERARATNA A T ET AL: "Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. AUG 2001, vol. 7, no. 8, August 2001 (2001-08-01), pages 2237 - 2245, XP009053624, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
CA2443144A1 (en) 2002-10-10
JP2004527244A (ja) 2004-09-09
WO2002079498A1 (en) 2002-10-10
EP1385983A1 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
HRP20041029A2 (en) Therapeutic use of selcetive pde10 inhibitors
IL176233A0 (en) Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
IL173490A0 (en) 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
IL149106A0 (en) Therapeutic use of selective pde10 inhibitors
IL173967A0 (en) Lipid system and methods of use
PL378294A1 (pl) Pochodne izochinolinowe i sposoby ich stosowania
EP1648282A4 (en) DETACHABLE CRYO-SURGICAL PROBE
HUP0400300A3 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU2003254053A8 (en) Pyrazolopyrimidines as protein kinase inhibitors
GB0025782D0 (en) Use of inhibitors
PL1622897T3 (pl) Inhibitory 3-kinazy fosfatydyloinozytolu
AU2003238772A8 (en) In vitro evaluation of nucleic acid ligands
IL159506A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
SG112017A1 (en) Method of determining shape data
IL164849A0 (en) Methods for measuring kinase activity and phosphatase activity
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1642978A4 (en) METHOD FOR DETECTING SARS CORONAVIRUS
IL162511A (en) Method for determining the biological activity of defibrotide
AU1183902A (en) Methods for parallel measurement of genetic variations
IL150167A0 (en) Method for in vivo sensing
IL155908A0 (en) Method of measuring low impedances
IL157024A0 (en) Il-18 inhibitors in heart disease
AU2003288699A8 (en) Method for in vivo sensing
AU2003253850A8 (en) Non-invasive measurement of ph
IL162481A0 (en) Method and use of determining genotype

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20051006

RTI1 Title (correction)

Free format text: METHOD OF DETERMINING THE IN-VIVO ACTIVITY OF RECEPTOR-TYPE KINASE INHIBITORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071030